The Full Wiki

More info on PF-219,061

PF-219,061: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

PF-219,061
Systematic (IUPAC) name
(R)-3-(4-propylmorpholin-2-yl)phenol
Identifiers
CAS number  ?
ATC code  ?
PubChem 9794475
Chemical data
Formula C 13H19NO2  
Mol. mass 221.295 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes Nasal

PF-219,061 is a drug developed by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor.[1][2] It is under development as a potential medication for the treatment of female sexual dysfunction.[3][4]

See also

References

  1. ^ Blagg J, Allerton CM, Batchelor DV, Baxter AD, Burring DJ, Carr CL, Cook AS, Nichols CL, Phipps J, Sanderson VG, Verrier H, Wong S. Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route. Bioorganic and Medicinal Chemistry Letters. 2007 Dec 15;17(24):6691-6. PMID 17976986
  2. ^ Brioni JD, Moreland RB. Dopamine D4 receptors and the regulation of penile erection. Drug Discovery Today: Therapeutic Strategies. 2006;3(4):599-604. doi:10.1016/j.ddstr.2006.10.006
  3. ^ Van Der Graaf et al. SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION. WIPO Patent WO/2003/051370, granted to Pfizer.
  4. ^ Attkins NJ, Heatherington AC, Phipps J, Verrier H, Huyghe I. Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061. Xenobiotica. 2009 Jul;39(7):523-33. PMID 19480558
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message